A new treatment option for patients with renal cancer

December 20, 2007

Treatment with bevacizumab plus interferon improves progression-free survival in patients with metastatic renal cell carcinoma compared with interferon alone, and will provide a new first-line treatment option for patients with renal cancer, according to an Article in this week's issue of The Lancet.

There are 120 000 new cases of renal cell carcinoma in Europe and the USA every year, and it causes 60 000 deaths. Until recently the standard treatment options for metastatic renal cell carcinoma were limited to immunotherapy with either interleukin 2 or interferon, both of which had modest response rates (<20%) along with substantial toxicities. Newer antiangiogenesis-targeting agents* such as sunitinib, and temsirolimus have provided further options for treatment and improved prognosis in patients with metastatic renal cell carcinoma. Bevacizumab, another antiangiogenesis-targeting agent, has shown an improvement in time to progression in phase II studies of metastatic renal cell carcinoma, and has a well-defined safety profile that includes more than 10 000 patients.

Dr Bernard Escudier (Institut Gustave Roussy, Villejuif, France) and colleagues did an international, multicentre, randomised, double-blind, phase III trial of 649 patients with previously untreated metastatic renal cell carcinoma to determine whether first-line treatment with bevacizumab plus interferon alfa improved efficacy compared to interferon alfa alone. The authors unblinded their study early. Data for the primary endpoint of overall survival were not mature, but the secondary endpoint of progression-free survival from the interim analysis were sufficient for reporting.

325 patients received bevacizumab with interferon and 316 received placebo plus interferon. According to the authors there were 230 progression events in the bevacizumab plus interferon alfa group and 275 in the control group. There were 114 deaths in the bevacizumab plus interferon alfa group and 137 in the control group. The authors note that median progression-free survival was significantly longer in the bevacizumab arm compared with the control group (10.2 months vs 5.4 months). Furthermore, the safety profile was consistent with previous observations, and the grade 3/4 adverse events were manageable with standard therapies.

The authors conclude: "This treatment [bevacizumab plus interferon] is clearly comparable with the most active treatment, and with a very good safety profile, will provide new options for renal cancer patients."** They go on: "The availability of a variety of active agents provides increased treatment options and the opportunity to provide several lines of therapy and improved survival."

In an accompanying Comment, Dr Robert Motzer and Dr Ethan Basch (Memorial Sloan-Kettering Cancer Center, New York, USA) say: "Phase II trials of bevacizumab as first-line and second-line monotherapy report response rates (15% and 10% respectively) similar to those observed with interferon alone. The high response rate (31%) seen in Escudier's trial suggests that interferon does contribute to the efficacy of this regimen." They go on: "The study supports the vascular endothelial growth factor blockade as a therapeutic approach to the treatment of metastatic renal cell carcinoma and highlights the need for further research to define the optimum in the rapidly changing era of targeted therapy".
-end-
Dr Bernard Escudier, Institut Gustave Roussy, Villejuif, France. escudier@igr.fr T) +33 1 42 11 54 10

Comment Jeanne D'Agostino, Media Relations, Memorial Sloan-Kettering Cancer Center, New York, USA. dagostij@mskcc.org T) +1 646 227 3137

Notes to Editors

*.Antiangiogenesis-targeting agents stop tumor growth by preventing the formation of new blood vessels by targeting and inhibiting the function of a natural protein called vascular endothelial growth factor (VEGF) that stimulates new blood vessel formation.

**Quote directly from author and cannot be found in the articleView the paper associated with this press release at http://multimedia.thelancet.com/pdf/press/Renal.pdf

Lancet

Related Immunotherapy Articles from Brightsurf:

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020) .

Precision chemo-immunotherapy for pancreatic cancer?
Pancreatic cancer is highly lethal: according to the National Cancer Institute, only about 10 percent of patients remain alive five years after diagnosis.

Taking the itch out of cancer immunotherapy
Researchers from the University of Tsukuba have determined that PD-1 expression on CD8 T cells is the biological pathway that leads to psoriasis-like dermatitis, an unfavorable side effect of cancer immunotherapy with PD-1 inhibitors.

Prostate cancer: immunotherapy offers hope
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.

New immunotherapy to beat cancer
Sophie Lucas (University of Louvain de Duve Institute) and her team succeeded in neutralising a molecule that blocks the immune system against cancer.

New hydrogels for T-cell growth to be used in cancer immunotherapy
A team with the participation of researchers from the Spanish National Research Council (CSIC) has designed new hydrogels that allow the culture of T-cells or T-lymphocytes, cells of the immune system that are used in cancer immunotherapy since they have the capacity to destroy tumor cells.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

A blood test could predict who benefits from immunotherapy
A test which detects changing levels of tumour fragments in the blood may be an easy, non-invasive and quick way to predict who will benefit from immunotherapy, a treatment option for advanced cancers.

Immunotherapy safe for patients with COVID-19, cancer
Preliminary data from researchers at the University of Cincinnati Cancer Center show that immunotherapy doesn't necessarily worsen complications for patients with both COVID-19 and cancer.

A helping hand for cancer immunotherapy
Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

Read More: Immunotherapy News and Immunotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.